MAYNF (Mayne Pharma Group) Owner Earnings per Share (TTM): -0.83 (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MAYNF Mayne Pharma Group Ltd MAYNF
52 GF Score
Price $2.08
GF Value $3.99
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Mayne Pharma Group Owner Earnings per Share (TTM)?

Mayne Pharma Group MAYNF +5.44% 52 Owner Earnings per Share (TTM) is -0.83 as of Jun. 2025. GuruFocus rates MAYNF with a GF Score™ of 52/100 and a GF Value™ of $3.99 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 64 Medical Distribution companies, Mayne Pharma Group ranks worse than 1562498.44% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Mayne Pharma Group's Owner Earnings per Share (TTM) ended in Jun. 2025 was $-0.83. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Mayne Pharma Group's Owner Earnings per Share (TTM) or its related term are showing as below:


During the past 13 years, the highest Price-to-Owner-Earnings ratio of Mayne Pharma Group was 55.78. The lowest was 2.33. And the median was 5.64.


MAYNF's Price-to-Owner-Earnings is not ranked *
in the Medical Distribution industry.
Industry Median: 11.69
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Mayne Pharma Group's Earnings per Share (Diluted) for the six months ended in Dec. 2025 was $-0.12. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.69. It's PE Ratio (TTM) ratio for today is At Loss.

Mayne Pharma Group's EPS without NRI for the six months ended in Dec. 2025 was $-0.09. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.67. It's PE Ratio without NRI ratio for today is At Loss.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Mayne Pharma Group Owner Earnings per Share (TTM) Related Terms


Mayne Pharma Group Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for Mayne Pharma Group's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mayne Pharma Group Owner Earnings per Share (TTM) Chart

Mayne Pharma Group Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.81 -1.77 0.75 -1.37 -0.72

Mayne Pharma Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -1.37 0.00 -0.72 0.00

MAYNF vs MCK, CAH, COR: Owner Earnings per Share (TTM) Comparison

For the Medical Distribution subindustry, Mayne Pharma Group's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mayne Pharma Group Price-to-Owner-Earnings vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Mayne Pharma Group's Price-to-Owner-Earnings falls into.


MAYNF
52GF Score
Mayne Pharma Group Ltd MAYNF
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mayne Pharma Group Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Mayne Pharma Group's Owner Earnings per Share (TTM) Calculation:

Last Year Average of Last 5 Years
Net Income -61.1
Depreciation, Depletion and Amortization 45.1
Change In Deferred Tax 0.0
5Y Average of Maintenance Capital Expenditure 41.2
Change In Working Capital 0.0
Shares Outstanding (Diluted Average) 79.1

1. Start with "Net Income" from income statement. Mayne Pharma Group's Net Income for the trailing twelve months (TTM) ended in Jun. 2025 was $-61.1 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Mayne Pharma Group's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Jun. 2025 was $45.1 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Mayne Pharma Group's Change In Deferred Tax for the trailing twelve months (TTM) ended in Jun. 2025 was $0.0 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $41.2 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Mayne Pharma Group's 5-Year Average Maintenance Capital Expenditure = $41.2 Mil

5. "Change In Working Capital" is from cashflow statement. Mayne Pharma Group's Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2025 was $0.0 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Mayne Pharma Group's Shares Outstanding (Diluted Average) for the months ended in Jun. 2025 was 79.139 Mil.

Mayne Pharma Group's Onwer Earnings Per Share for Jun. 2025 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -61.091 +45.095+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-41.172+0)/79.139
=-0.83

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=2.08/-0.83
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of -0.83 mean?
Mayne Pharma Group (MAYNF) has a Owner Earnings per Share (TTM) of -0.83 as of Jun. 2025. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Mayne Pharma Group. Over the past decade, Mayne Pharma Group's Owner Earnings per Share (TTM) has ranged from 2.33 to 55.78. According to the industry distribution chart, Mayne Pharma Group ranks #999999 out of 64 companies in the Medical Distribution industry.
Is Mayne Pharma Group's Owner Earnings per Share (TTM) too high?
Mayne Pharma Group's current Owner Earnings per Share (TTM) is -0.83. Over the past 10 years, this metric has ranged from a low of 2.33 to a high of 55.78. Based on the distribution chart, Mayne Pharma Group ranks #999999 out of 64 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Mayne Pharma Group has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's Owner Earnings per Share (TTM) compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Mayne Pharma Group ranks #999999 out of 64 companies for Owner Earnings per Share (TTM). This places Mayne Pharma Group in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 11.69. Historically, Mayne Pharma Group's own Owner Earnings per Share (TTM) has ranged from 2.33 to 55.78 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Medical Distribution company?
The median Owner Earnings per Share (TTM) among Medical Distribution companies is 11.69, based on 64 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Mayne Pharma Group. For the Medical Distribution industry, the median Owner Earnings per Share (TTM) is 11.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayne Pharma Group's current Owner Earnings per Share (TTM) is -0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (MAYNF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.99, compared to a current price of $2.08 — trading 47.9% below its estimated fair value. The current Owner Earnings per Share (TTM) is -0.83. Mayne Pharma Group's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Mayne Pharma Group (MAYNF), the current Owner Earnings per Share (TTM) is -0.83 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mayne Pharma Group (MAYNF) Overvalued in 2026?

Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued. The current stock price of $2.08 is trading 47.9% below its estimated GF Value™ of $3.99. GuruFocus considers Mayne Pharma Group to be Possible Value Trap.

Key valuation signals for MAYNF:

  • Owner Earnings per Share (TTM): -0.83
  • GF Value™: $3.99 vs. price of $2.08 (47.9% below fair value)
  • GF Score™: 52/100 with 3 warning signs

No single metric tells the full story. See the MAYNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mayne Pharma Group Business Description

Other Exchanges MYX:Australia
Address 1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
52GF Score

Get the complete analysis for MAYNF

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.08
Price
$3.99
GF Value